同用名/別名(Synonym)
Hepatocyte growth factor; HPTA; HGF; SF; Scatter factor; Hepatopoietin-A
描述(Description)
HGF, is a pleiotropic protein in the Plasminogen subfamily of S1 peptidases and contains 4 kringle domains, 1 PAN domain and 1 peptidase S1 domain. HGF is secreted as an inactive 728 amino acid (aa) single chain propeptide. It is cleaved after the fourth Kringle domain by a serine protease to form bioactive disulfide-linked HGF with a 60 kDa alpha and 30 kDa beta chain. HGF binds heparan-sulfate proteoglycans and the widely expressed receptor tyrosine kinase, HGF R/c-MET. HGF regulates epithelial morphogenesis by inducing cell scattering and branching tubulogenesis. It can also alter epithelium morphology by the induction of nectin-1 alpha ectodomain shedding, an adhesion protein component of adherens junctions. HGF regulates cell growth, cell motility, and morphogenesis by activating a tyrosine kinase signaling cascade after binding to the proto oncogenic c-Met receptor. HGF is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorogenesis, and tissue regeneration.
純度(Purity)
≥95%, by SDS-PAGE (under reducing (R) & Non-reducing conditions, visualized by Coomassie staining)
生物活性(Bioactivity)
Determined by its ability to inhibit the proliferation of mouse MPC-11 cells. The expected ED50 is ≤ 2.0 ng/ml, corresponding to a specific bioactivity of ≥ 5 x 105units/mg
氨基酸序列(Target Protein Sequence)
QRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCADNTMNDTDVPLETTECIQGQGEGYRGTVNTIWNGIPCQRWDSQYPHEHDMTPENFKCKDLRENYCRNPDGSESPWCFTTDPNIRVGYCSQIPNCDMSHGQDCYRGNGKNYMG/VAIL NLSQTRSGLTCSMWDKNMEDLHRHIFWEPDASKLNENYCRNPDDDAHGPWCYTGNPLIPWDYCPISRCEGDTTPTIVNLDHPVISCAKTKQLR&VVNGIPTRTNIGWMVSLRYRNKHICGGSLIKESWVLTARQCFPSRDLKDYEAWLGIHDVHGRGDEKCKQVLNVSQLVYGPEGSDLVLMKLARPAVLDDFVSTIDLPNYGCTIPEKTSCSVYGWGYTGLINYDGLLRVAHLYIMG/VAIL NEKCSQHHRGKVTLNESEICAGAEKIGSGPCEGDYGGPLVCEQHKMRMVLGVIVPGRGCAIPNRPGIFVRVAYYAKWIHKIILTYKVPQS
制劑(Trait)
Lyophilized from a 0.22 μm filtered solution of PBS or PBS, pH 7.4, 8% trehalose
復(fù)溶(Reconstitution)
Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
保存條件&效期(Storage & Stability)
36 months at 2°C to 8°C in lyophilized state.
6 months at -20°C to -80°C under sterile conditions after reconstitution.
7-10 days at 2°C to 8°C under sterile conditions after reconstitution.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
運(yùn)輸方式(Shipping)
The product is shipped with blue ice.

生物活性(Bioactivity)
Measured by its ability to induce IL-11 secretion by Saos2 human osteosarcoma cells.
The ED50 for this effect is ≤2.5 ng/ml.
The bioactivity of Y01701 was higher than the other competing product.

電泳(SDS-PAGE)
Greater than 95% as determined by reducing SDS-PAGE. Human HGF is initially produced as a single, inactive polypeptide and is subsequently cleaved by serine proteases to generate a 69-kDa α chain and a 34-kDa β chain. The free α and β chains then combine to form an active heterodimer through the formation of disulfide bonds between cysteine residues. Under reducing conditions (SDS-PAGE), the protein exhibits apparent molecular masses of 90, 60, and 34 kDa, which correspond to the heavy α chain and the light β chain, respectively, due to glycosylation.
特別提示:本公司的所有產(chǎn)品僅用于工業(yè)應(yīng)用或者科學(xué)研究等非醫(yī)療目的,不可用于人類或動物的臨床診斷或者治療,非藥用,非食用。
關(guān)鍵字: GMP級;高純度;批間一致;生物活性;科研專供;
在生物科技領(lǐng)域,豐度蛋白專注重組蛋白供應(yīng),以“豐度的風(fēng)帆為蛋白提供動力,豐度為蛋白護(hù)航”為使命,賦能生命科學(xué)發(fā)展。
蘇州豐度依托先進(jìn)技術(shù)平臺,打造成熟生產(chǎn)體系,嚴(yán)控基因工程設(shè)計(jì)、細(xì)胞培養(yǎng)、蛋白純化等環(huán)節(jié),優(yōu)化工藝與管理,確保產(chǎn)品高純度、高活性且批間一致。產(chǎn)品覆蓋基礎(chǔ)研究、生物醫(yī)藥研發(fā)等多領(lǐng)域,為科研及生產(chǎn)提供多樣、適配產(chǎn)品,助力突破技術(shù)難題 。